Compare TOL & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOL | NBIX |
|---|---|---|
| Founded | 1967 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 13.2B |
| IPO Year | 1994 | 1996 |
| Metric | TOL | NBIX |
|---|---|---|
| Price | $147.06 | $132.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 22 |
| Target Price | $164.44 | ★ $180.82 |
| AVG Volume (30 Days) | ★ 1.1M | 950.3K |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 2.19 | ★ 4.67 |
| Revenue | ★ $7,143,258,000.00 | $161,626,000.00 |
| Revenue This Year | N/A | $22.85 |
| Revenue Next Year | $6.01 | $10.36 |
| P/E Ratio | $63.47 | ★ $27.47 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $90.78 | $98.95 |
| 52 Week High | $168.36 | $160.18 |
| Indicator | TOL | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 59.38 | 54.14 |
| Support Level | $128.61 | $124.29 |
| Resistance Level | $150.45 | $136.23 |
| Average True Range (ATR) | 3.91 | 4.21 |
| MACD | 1.43 | 0.12 |
| Stochastic Oscillator | 86.26 | 85.22 |
Toll Brothers Inc is the luxury homebuilder in the USA, operating in over 60 markets across 24 states. The Fort Washington, Pennsylvania-headquartered homebuilder caters to affluent first-time, move-up, active-adult, and second-homebuyers. Toll Brothers has shifted in recent years to a greater mix of speculative, or "quick move-in" homes. The homebuilder has also expanded its price points, with a greater emphasis on "affordable luxury. Traditional homebuilding accounts for the majority of Toll Brothers' earnings, but the firm also offers ancillary mortgage, title, insurance, and other services.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.